Theratechnologies Announces Certain Preliminary Q3 2023 Financial Highlights. com uses cookies on this site. com uses cookies on this site. The firm offers its product under the brand name of. 9% more than in 2021. This news release constitutes a "designated news release" for the purposes of. communications@theratech. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies,. MONTREAL, Nov. 15, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. com uses cookies on this site. Theratechnologies Inc (Theratechnologies) is a biopharmaceutical company that focuses on the discovery and development of drugs for people with orphan medical conditions. The business had revenue of $27. We also use them to share usage. Company Type For Profit. 23 to a day high of $1. Jours fériés des marchés. Theratechnologies Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update. (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its first quarter 2023 ended February 28, on Wednesday, April 12. com uses cookies on this site. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650For the three- and six-month periods ended May 31, 2023, consolidated revenue was $17,549,000 and $37,457,000, compared to $19,268,000 and $37,825,000 for the same periods ended May 31, 2022. MONTREAL, Feb. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today presented preclinical data that demonstrate the potential utility of its lead investigational. The SORT1 receptor plays a significant role in protein internalization, sorting and trafficking. Amendments Allow Theratechnologies to Maintain Minimum Liquidity of US$15 Million up to and until October 31, 2023. 30, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. MONTREAL, May 09, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (2020-10-16 | TSX:TH) Theratechnologies Appoints Two New Board Members. 26, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Theratechnologies Inc. TH1902 is currently Theratechnologies’ lead investigational PDC candidate for the treatment of cancer derived from its SORT1+ Technology™. 1-438. com. FY2023 revenue guidance range set between $90 million and $95 million. 617-356-1009. com. The Montreal-based biopharmaceutical company's consolidated net revenues for fourth quarter 2020 are expected to be between US$18. com uses cookies on this site. 250 Howe Street, Suite 1400 Vancouver, British Columbia, V6C 3S7 Click to expand. 40%. 4%. Theratechnologies Announces Finalization of Amendments to Some of the Terms and Conditions of its Credit Agreement with Marathon;. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a. The ADRIQ (Association pour le développement de la recherche et de l’innovation du Québec) rewards Quebec-based companies for leadership and innovation in their respective. By continuing to use our service, you agree to our use of cookies. (THTX) NasdaqCM - NasdaqCM Real Time Price. Stockhouse. 514-336-7800. com uses cookies on this site. View analysts price targets for THTX. stock news by MarketWatch. 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 6. 2015 Peel Street, 11th Floor Montréal, Québec Canada H3A 1T8 Phone: 514 336-7800 Fax: 514 331-9691Theratechnologies Announces Amendment to its Term Loan Facility With Affiliates of Marathon Asset Management. (TH. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic. Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will report financial results and provide a business update for. TH | September 5, 2023. We also use them to share usage information with our partners. 2% per year. (TH. Theratechnologies Inc. Metastasis is a form of cancer that has spread from its original site to a distant site or organ where it grows or metastasizes. Katana shareholders will. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced it will report financial results and provide a business update for its second quarter. ) Clinical-stage pharmaceutical company Theralase Technologies Inc. This news release constitutes a. 36 morning pop. MONTREAL, Dec. 19, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. On July 28, 2023, Theratechnologies announced that the Company had entered into an agreement with certain funds and accounts for which Marathon Asset Management, L. Cookies are used to offer you a better browsing. It is highly expressed in cancer cells compared to healthy tissue, which makes SORT1 an. TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (Sort1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth Sep 13. 1-438. T. . NCU. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced it will report financial results and provide a business update for its second. Theratechnologies Inc. 69, 1. View real-time stock prices and stock quotes for a full financial overview. Heures de négociation. We also use them to share usage. com uses cookies on this site. Theratechnologies Announces 1-for-4 Reverse Stock Split. Senior Director, Investor Relations. MONTREAL, Aug. Find the latest Theratechnologies Inc. TH | September 26, 2023. By continuing to use our service, you agree to our use of cookies. By continuing to use our service, you agree to our use of cookies. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 2% to $21. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. For investor inquiries: Leah Gibson. 25 to $1. (2013-04-03 | TSX:TH) Theratechnologies Inc. FAQ – Utilisateurs de TMX Argent NOUVEAU. com. Cookies are used to offer you a better browsing experience and to analyze our. 57%) Q1 2020 Earnings Call. 9 million, adjusted EBITDA of $2. By continuing to use our service, you agree to our use of cookies. com uses cookies on this site. (THTX) Stock Price, Quote, latest community messages, chart, news and other stock related information. TH | September 5, 2023. Stockhouse. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced receipt of the 2023 Industrial Research Sectoral Group (RSRI) Innovation Award from the CQDM (for. The company reported ($0. Theratechnologies Inc. The Montreal-based biopharmaceutical company's consolidated net revenues for fourth quarter 2020 are expected to be between US$18. Stockhouse. 20% from a day low at $1. MONTREAL, Feb. 38. 04, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that it plans to pursue Phase 3 clinical development of tesamorelin for the treatment of Non-Alcoholic Steatohepatitis (NASH) in. com uses cookies on this site. 49%) At close: 04:00PM EST 1. (2021-06-30 | TSX:TH) CORRECTION: Theratechnologies to Announce Financial Results for Its Second Quarter Fiscal 2021. European Headquarters. (Translation of registrant’s name into English) 2310 Alfred-Nobel Boulevard . By continuing to use our service, you agree to our use of cookies. Biopharmaceutical company Theratechnologies Inc. Stockhouse. Amendment Withdraws the Condition to File HFS Report to the FDA to Access the US$20 Million Second Tranche. MONTREAL, Aug. (2023-07-21 | TSX:TH) Theratechnologies Announces the Resignation of One of Its Directors, Mr. (NASDAQ:NASDAQ:THTX) Q1 2021 Earnings Conference Call April 14, 2021 8:30 AM ETCompany ParticipantsDenis Boucher - Vice President,. , a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. com uses cookies on this site. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis. FDA for its IV push form of administration of Trogarzo. Theratechnologies to Present at the Credit Suisse 30th Annual Healthcare Conference on November 11, 2021 Globe Newswire - Wed Nov 3, 2021 . By continuing to use our service, you agree to our use of cookies. One reason for that is that this tier does not include penny stocks. MONTREAL, July 23, 2021 /CNW Telbec/ - Theratechnologies Inc. The Notes were issued under a trust indenture dated as of June 19, 2018, by and among Theratechnologies and Computershare Trust Company of Canada. THTX | Complete Theratechnologies Inc. Philippe Dubuc Senior Vice President and Chief Financial Officer Phone: +1-438-315-6608 ir@theratech. Theratechnologies Appoints New Board Member. 81 million for the quarter. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies Receives January 2024 PDUFA Goal Date for Tesamorelin F8 Formulation sBLA. Headquartered in Montreal, Theratechnologies is a biotech company that develops innovative therapies for unmet medical needs in HIV, oncology, and NASH, a type of liver disease. Stockhouse. 4. a biopharmaceutical company focused on the development and commercialization of innovative therapies, today initiated enrollment of patients in the basket portion of the first-in-human study of TH1902, Theratechnologies’ investigational lead peptide drug conjugate (PDC) for the treatment of sortilin-expressing. This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its. TH | October 13, 2022 - Q3 2022 Consolidated. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Theratechnologies (TSX:TH)has indicated that Trogarzo did not meet its primary endpoints in its IM method study. com uses cookies on this site. Company Participants. 72%. By continuing to use our service, you agree to our use of cookies. 00. 2015 Peel Street, 11th Floor Montréal, Québec Canada H3A 1T8 Phone: 514 336-7800 Fax: 514 331-9691 Theratechnologies Announces Amendment to its Term Loan Facility With Affiliates of Marathon Asset Management. com uses cookies on this site. com uses cookies on this site. W. (“Theratechnologies”, the “Company”, or “we”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has completed the previously announced consolidation of the issued. Story. L. (2022-02-10 | TSX:TH) Theratechnologies to Announce Financial Results for Its Fourth Quarter and Full Fiscal Year 2021. We also use them to share usage. Theratechnologies Inc. 54% and a negative trailing twelve-month return on equity of. Montréal, Québec, Canada . MONTREAL, July 07, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the second quarter and first half of fiscal. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Approximately US$2,000,000, or CA$2,600,000, was paid in cash at closing. com. Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has established an at-the-market ("ATM") equity program allowing Theratechnologies to issue and sell up to US $50 million common shares from. com uses cookies on this site. A high-level overview of Theratechnologies Inc. $30. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and. About Theratechnologies Theratechnologies (Nasdaq: THTX) (TSX: TH) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. MONTREAL, Oct. This work is well underway and will be considered by the SAC as part of their meeting, which is scheduled for the latter half of March when the analyses are expected to be ready. The company’s previously announced offering was conducted by a syndicate of underwriters, including companies such as Canaccord Genuity. 9 million as at August 31, 2023. Find the latest Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its third quarter of fiscal 2022 ended August 31, on Thursday, October 13. Q4 2022 consolidated revenue growth of 14. TH | March 7, 2023. S. 7 ( 1D) About THTX In 2022, THTX's revenue was 80. Stockhouse. 16, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Real-time Price Updates for Theratechnologies (TH-T), along with buy or sell indicators, analysis, charts, historical performance, news and more(2018-03-06 | TSX:TH) Theratechnologies Announces FDA Approval of Breakthrough Therapy, Trogarzo™ (ibalizumab-uiyk) Injection, the First HIV-1 Inhibitor and Long-Acting Monoclonal Antibody for Multidrug Resistant HIV-1. com uses cookies on this site. TH | October 13, 2022. MONTREAL, July 14, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 05M. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650WELCOME TO SEDAR+ File, disclose and search for issuer information in Canada’s capital markets Search SEDAR+ All public disclosure documents Reporting Issuers List Filing organizations from all jurisdictions Disciplined List People and companies under disciplinary action Cease Trade Orders People and companies restricted from trading securities Sign. Free cash flow. Find the latest Theratechnologies Inc. 2% for this period. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. By continuing to use our service, you agree to our use of cookies. 22, 2023 (GLOBE NEWSWIRE) -- B2Gold Corp. 02, 2023 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. Conjugating the short peptide with various anti-cancer agents allows for. Stockhouse. Further. We also use them to share. (2020-11-03 | TSX:TH) Theratechnologies Announces Departure of Chief Commercial Officer. Currency in USD Follow 2W 10W 9M 1. Theratechnologies Announces Certain Preliminary Q3 2023 Financial Highlights. Theratechnologies last announced its earnings data on September 26th, 2023. Cookies are used to offer you a better browsing experience and to analyze our traffic. (2022-04-27 | TSX:TH) Theratechnologies to Focus Its Commercialization Activities on the North American Territory. Investor Relations. MONTREAL, April 03, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Stockhouse. org. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has closed its previously announced publi. THTX | Complete Theratechnologies Inc. There are 102 news items for this page. (“Teuton” or “the Company”) (TSXV:TUO) (Frankfurt:TFE) has received news from its joint venture partner, Tudor Gold Corp. T. We also use them to share usage. 33. MONTREAL, Sept. Share your ideas and get valuable. Stockhouse. This news release constitutes a “designated news release” for the purposes of the. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development. - Q3 2022 North American Revenue Growth of 19%. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. By continuing to use our service, you agree to our use of cookies. TH | February 28, 2023. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development. TMX Group Limited and its affiliates do not endorse or recommend any securities issued by any companies identified on, or linked through, this site. By continuing to use our service, you agree to our use of cookies. 1-514-336-7800. We currently market prescription products for people with HIV in the United States. Their average twelve-month price target is $36. Further. Volume has increased on the last day along with the price, which is a. 31, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Headquarters. About Theratechnologies Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of. TO) Stock Price, News, Quote & History - Yahoo Finance Canada Markets close in 43 mins S&P/TSX 20,125. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Biopharmaceutical company Theratechnologies (TH) has closed its bought deal public offering after raising over C$58 million in proceeds. (2022-10-26 | TSX:TH) Theratechnologies Reports Data Showing High Expression of Sortilin (SORT1) in Multiple Solid Tumors from Tissue Microarrays. T. com. Senior Director, Investor Relations. By continuing to use our service, you agree to our use of cookies. (THTX) Stock Price, Quote, latest community messages, chart, news and other stock related information. ("Theratechnologies" or the "Company"). Q3 2023 consolidated revenue of $20. US Headquarters. , a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced further changes to its operations that will see a tapering. $30. Microsoft to invest $500M in Quebec AI economy. 82 million. Stockhouse. The abstracts are now available at aacr. See the latest Theratechnologies Inc stock price (THTX:XNAS), related news, valuation, dividends and more to help you make your investing decisions. “This is yet another major achievement for our oncology program. 2 million. com uses cookies on this site. 1300 (+9. Theratechnologies . Background: Breast and ovarian cancer stem cells (CSC) can contribute to the invasive and chemoresistance phenotype of tumors. MONTREAL, July 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies layoffs. The company offers EGRIFTA and EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus. 54% and a negative trailing twelve-month return on equity of 1,116. A live webcast of Dr. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the. S. Herein, we report. We also use them to share usage. Phone Number (514) 336-7800. 22, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies Inc. 26 +15. By continuing to use our service, you agree to our use of cookies. Common Shares (THTX) Stock Price, Quote, News & History | Nasdaq Nasdaq Data Link's products page Investors may trade in the Pre-Market (4:00. Elif McDonald - Senior Director, Investor Relations. Betteryear2. Stockhouse. MONTREAL, Dec. S. 08). Theratechnologies is leveraging its SORT1+ Technology™ to develop a new class of therapy that targets sortilin (SORT1)-positive cancers by linking anticancer drugs to proprietary peptides that specifically bind to the sortilin receptor. 04) earnings per share (EPS) for the quarter. Cookies are used to offer you a better browsing experience and to analyze our traffic. NEW YORK, Dec. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Get the latest Theratechnologies Inc (THTX) real-time quote, historical performance, charts, and other financial information to help you make more informed. By continuing to use our service, you agree to our use of cookies. Theratechnologies’ CFO to Attend Cantor Global Healthcare Conference in New York City Theratechnologies' CFO to Attend Piper Jaffray 31st Annual Healthcare Conference in New York City Stockhouse. Theratechnologies’ CFO to Attend Cantor Global Healthcare Conference in New York City. Cookies are used to offer you a better browsing experience and to analyze our traffic. By continuing to use our service, you agree to our use of cookies. By continuing to use our service, you agree to our use of cookies. The company’s marketed products include Egrifta SV is indicated to reduce excess abdominal fat in human immunodeficiency virus (HIV. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the. (THTX) stock. View real-time stock prices and stock quotes for a full financial overview. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies announced today that it will report its financial results for the second quarter of fiscal 2021 ended May 31, 2021 on Wednesday. 11/05/2020 4:15:02 PM. Sol-Gel Technologies (NASDAQ:SLGL) and Theratechnologies (NASDAQ:THTX) are both small-cap medical companies, but which is the better investment?We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, community ranking, risk,. -4. It’s lead investigational peptide drug conjugate linked to docetaxel, a well-established and well-characterized cytotoxic agent used in the treatment of. By continuing to use our service, you agree to our use of cookies. Further. (TSX: TH) (NASDAQ: THTX) (“Theratechnologies”), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its fourth quarter and full year fiscal 2022 ended November 30, on Tuesday, February 28, 2023. 2. TH1902 is currently Theratechnologies’ lead investigational PDC candidate for the treatment of cancer derived from its SORT1+ Technology™. THERATECHNOLOGIES INC. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company will present data from tissue microarrays showing high. FY2023 revenue guidance range set between $90 million and $95 million. Ibalizumab-uiyk (Trogarzo) is a medical infusion treatment for HIV infection in adults for whom other HIV medicines have not worked. Theratechnologies’ Ibalizumab Demonstrates Cost-Effectiveness as an Addition to Routine Clinical Care in Heavily Treatment-Experienced People with HIV. 3089 Background: SORT1 is expressed in a variety of tumors when compared to most healthy tissue. (“Theratechnologies” or the “Company”) (Nasdaq: THTX; TSX: TH), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has closed its previously announced publi. Cookies are used to offer you a better browsing experience and to analyze our traffic. This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021. Theratechnologies Inc. (2022-07-27 | TSX:TH) Theratechnologies Announces Closing of Funding of $40 Million Under the Terms of its Credit Agreement Stockhouse. Clinical-stage pharmaceutical company Theralase Technologies Inc. The company's proprietary technologies include Long Acting Peptides, a peptide stabilization technology that. This suggests a possible upside of 2,471. com. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 00 to $36. com uses cookies on this site. Register for your free account today at data. Further information about Theratechnologies is available on the Company’s website at on SEDAR+ at and. T. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will report financial results and provide a business update for its third. 69 to $1. MONTREAL, Nov. Theratechnologies Stock (NASDAQ: THTX) stock price, news, charts, stock research, profile. Join the discussion: Find out what everybody’s saying about this stock on the Theratechnologies Bullboard, and check out the rest of Stockhouse’s stock forums and message boards. has received a $100 million binding commitment with respect to a non-dilutive term loan with an affiliate of Marathon Asset Management. (2022-02-24 | TSX:TH) Theratechnologies Reports Financial Results for Fiscal 2021 and Provides Business Update. com. (2021-12-06 | TSX:TH) Theratechnologies Submits Supplemental Biologics License Application to FDA Advancing Development of IV Push Trogarzo® for Patients Living With HIV. : Renegotiated Lease to Generate Substantial Annual Savings. lgibson. Stockhouse. Cookies are used to offer you a better browsing experience and to analyze our traffic. TMX Group Limited and its affiliates do not endorse or recommend any securities issued by any companies identified on, or linked through, this site. S. Trogarzo® and. (2015-05-15 | TSX:TH) Authorization to Discontinue Class Action Proceedings Against Theratechnologies Granted. Cookies are used to offer you a better browsing experience and to analyze our traffic. Cookies are used to offer you a better browsing experience and to. Marsolais’ presentation will be available through. 12, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Senior Director, Communications & Corporate Affairs. com uses cookies on this site. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the second quarter and first half of. Join the discussion: Find out what everybody’s saying about this stock on the Theratechnologies Bullboard, and check out the rest of Stockhouse’s stock forums and message boards. 8. com. Stockhouse. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that President and CEO, Paul Lévesque has issued an open letter to shareholders. (TSE:TH) posted its quarterly earnings data on Tuesday, September, 26th. Theratechnologies Inc. Biopharma Theratechnologies (NASDAQ:THTX) Friday announced that a study evaluating an intramuscular (IM) method of administration for its therapy, Trogarzo, did not meet the primary endpoint. E-Poster website launch date and time: Saturday, April 10, 2021, 8:30 AM. Find more information. This is the list of the largest public listed companies in the Drug Manufacturers—Specialty & Generic industry from Canada by market capitalization with links to their reference stock. F8 formulation intended to replace EGRIFTA SV® with simplified dosing for the treatment of excess abdominal fat in adults with HIV and lipodystrophy.